A Phase I/II Study of Romidepsin in HIV-Infected Adults With Suppressed Viremia on Antiretroviral Therapy to Assess Safety, Tolerability, and Activation of HIV-1 Expression
Phase of Trial: Phase I/II
Latest Information Update: 24 May 2019
Price : $35 *
At a glance
- Drugs Romidepsin (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 07 Mar 2019 Results determining safety of multiple Romidepsin doses presented at the 26th Conference on Retroviruses and Opportunistic Infections.
- 31 Aug 2018 Biomarkers information updated
- 02 May 2018 Status changed from active, no longer recruiting to completed.